長時間作用型避妊薬市場：タイプ、製品、用途、最終用途別-2025～2030年の世界予測

長時間作用型避妊薬市場は、2023年に34億2,000万米ドルと評価され、2024年には36億8,000万米ドルに達すると予測され、CAGR 7.06％で成長し、2030年には55億2,000万米ドルに達すると予測されています。

長時間作用型避妊薬には、子宮内避妊器具（IUD）やホルモンインプラントなど、長期にわたって妊娠を予防するように設計された器具や薬剤が含まれます。その必要性は、特にヘルスケアへのアクセスが限られている地域において、効果的な家族計画に対する満たされていないニーズに対応し、最小限のユーザー介入で信頼性の高い避妊オプションを提供する能力によって強調されています。日常的な服薬アドヒアランスの問題のない、便利な避妊法を求める女性の間で広く使用されています。ヘルスケア施設、政府の家族計画イニシアティブ、リプロダクティブ・ヘルス向上を目指す非営利団体など、最終用途の範囲は多岐にわたる。市場の成長は、女性の健康に対する世界の関心の高まり、長時間作用型の避妊法に対する認識と受容の高まり、家族計画を支援する政府の取り組みによって推進されています。副作用の減少や有効性の向上につながる製品設計の技術的進歩も極めて重要です。ヘルスケア・インフラの成長とリプロダクティブ・ヘルスに対する社会的態度の変化により、新興市場には機会があふれています。企業は、これらの地域に効果的に浸透するために、啓発キャンペーンを行う地元政府とのパートナーシップを活用し、助成金プログラムを共同で実施すべきです。しかし、文化的・宗教的な抵抗感、訓練を受けたヘルスケア・プロバイダーの不足、エンドユーザーによっては初期費用が高いなどの障壁も残っており、市場導入が遅れる可能性もあります。規制上の課題や副作用に関する誤解が、市場力学をさらに複雑にしています。イノベーションを推進するために、企業は副作用の軽減に重点を置きながら、より使いやすく、可逆的で、費用対効果の高い方法の開発に注力すべきです。ヘルスケア提供者のトレーニングや患者教育プログラムを改善することで、誤解を緩和し、市場拡大を促進することができます。この市場の性質を理解するには、社会政治的要因による過敏性を認識すると同時に、的を絞ったアウトリーチ活動や技術強化を通じて、変革的成長の可能性を認識することが必要です。事業戦略を現地のヘルスケア政策と整合させ、長時間作用型避妊薬の利点に関する認識を高めることで、市場シェアを大幅に拡大することができます。

市場力学：急速に進化する長時間作用型避妊薬市場の主要市場インサイトを公開

長時間作用型避妊薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 男女における長期避妊の採用率の上昇
  • 公的資金による家族計画サービスの増加
• 市場抑制要因
  • 長期避妊に伴う副作用
• 市場機会
  • 技術的に進歩した長期避妊法のイントロダクション
  • LTCに対する政府の強力な支援
• 市場の課題
  • 限られた承認製品に関する懸念

ポーターのファイブフォース：長時間作用型避妊薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：長時間作用型避妊薬市場における外部からの影響の把握

外部マクロ環境要因は、長時間作用型避妊薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析長時間作用型避妊薬市場における競合情勢の把握

長時間作用型避妊薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス長時間作用型避妊薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、長時間作用型避妊薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨長時間作用型避妊薬市場における成功への道筋を描く

長時間作用型避妊薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 男女間で長期避妊の採用が増加
    • 公的資金による家族計画サービスの増加
  • 抑制要因
    • 長期避妊に伴う副作用
  • 機会
    • 技術的に進歩した長期避妊法のイントロダクション
    • LTCに対する政府の強力な支援
  • 課題
    • 承認された製品が限られていることに関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 長時間作用型避妊薬市場：タイプ別

• 長期避妊薬
• 短時間作用型避妊薬

第7章 長時間作用型避妊薬市場：製品別

• 注射剤
• 子宮内避妊器具
• 皮下インプラント

第8章 長時間作用型避妊薬市場：用途別

• 避妊
• HIV
• 統合失調症

第9章 長時間作用型避妊薬市場：最終用途別

• ドラッグストア
• eコマース
• 病院

第10章 南北アメリカの長時間作用型避妊薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の長時間作用型避妊薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの長時間作用型避妊薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Bayer AG
• DKT International
• HRA Pharma SAS by Perrigo Company plc
• Merck & Co., Inc.
• Meril Life Sciences Pvt. Ltd.
• Mona Lisa N.V.
• OCON Healthcare
• Pfizer Inc.
• Pregna International Limited
• Prosan International B.V.
• SMB Corporation of India
• Teva Pharmaceuticals Industries Ltd.
• The Cooper Companies, Inc.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. LONG-ACTING CONTRACEPTION MARKET RESEARCH PROCESS
• FIGURE 2. LONG-ACTING CONTRACEPTION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LONG-ACTING CONTRACEPTION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LONG-ACTING CONTRACEPTION MARKET DYNAMICS
• TABLE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY LONG-ACTING CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SHORT-ACTING CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBDERMAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CONTRACEPTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. POLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. QATAR LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM LONG-ACTING CONTRACEPTION MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 190. LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, 2023

The Long-acting Contraception Market was valued at USD 3.42 billion in 2023, expected to reach USD 3.68 billion in 2024, and is projected to grow at a CAGR of 7.06%, to USD 5.52 billion by 2030.

Long-acting contraception encompasses devices and medications designed to prevent pregnancy over an extended period, such as intrauterine devices (IUDs) and hormonal implants. Their necessity is underscored by their ability to provide reliable birth control options with minimal user intervention, addressing unmet needs for effective family planning, especially in regions with limited access to healthcare. Applications are widespread among women seeking convenient contraceptive solutions without daily adherence issues. The end-use scope is diverse, including healthcare establishments, government family planning initiatives, and non-profit organizations aiming to enhance reproductive health. Market growth is propelled by a rising global focus on women's health, increased awareness and acceptance of long-acting methods, and government initiatives supporting family planning. Technological advancements in product design, leading to fewer side effects and improved efficacy, are also pivotal. Opportunities abound in emerging markets due to growing healthcare infrastructure and shifting societal attitudes towards reproductive health. Companies should leverage partnerships with local governments for awareness campaigns and collaborate on subsidized programs to penetrate these regions effectively. However, barriers persist, such as cultural and religious reservations, lack of trained healthcare providers, and high initial costs for some end-users, which may stall market adoption. Regulatory challenges and misconceptions about side effects further complicate market dynamics. To drive innovation, businesses should focus on developing more user-friendly, reversible, and cost-effective methods, with an emphasis on reducing adverse effects. Improved healthcare provider training and patient education programs can mitigate misconceptions, fostering market expansion. Understanding the nature of this market involves acknowledging its sensitivity due to sociopolitical factors but also recognizing its potential for transformative growth through targeted outreach and technological enhancement. Aligning business strategies with local healthcare policies and enhancing awareness about long-acting contraceptive benefits can drive substantial market share gains.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Long-acting Contraception Market

The Long-acting Contraception Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising adoption of long term contraception among male and female
  • Rising publicly funded family planning services
• Market Restraints
  • Associated side effects of long term contraception
• Market Opportunities
  • Introduction of technically advanced long term contraception methods
  • Strong government support for LTC
• Market Challenges
  • Concern regarding limited approved products

Porter's Five Forces: A Strategic Tool for Navigating the Long-acting Contraception Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Long-acting Contraception Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Long-acting Contraception Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Long-acting Contraception Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Long-acting Contraception Market

A detailed market share analysis in the Long-acting Contraception Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Long-acting Contraception Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Long-acting Contraception Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Long-acting Contraception Market

A strategic analysis of the Long-acting Contraception Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Long-acting Contraception Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayer AG, DKT International, HRA Pharma SAS by Perrigo Company plc, Merck & Co., Inc., Meril Life Sciences Pvt. Ltd., Mona Lisa N.V., OCON Healthcare, Pfizer Inc., Pregna International Limited, Prosan International B.V., SMB Corporation of India, Teva Pharmaceuticals Industries Ltd., The Cooper Companies, Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Long-acting Contraception Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Long-Acting Contraceptives and Short-Acting Contraceptives.
• Based on Product, market is studied across Injectables, Intrauterine Devices, and Subdermal Implants.
• Based on Application, market is studied across Contraception, HIV, and Schizophrenia.
• Based on End-use, market is studied across Drug Store, E-Commerce, and Hospital.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising adoption of long term contraception among male and female
    • 5.1.1.2. Rising publicly funded family planning services
  • 5.1.2. Restraints
    • 5.1.2.1. Associated side effects of long term contraception
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of technically advanced long term contraception methods
    • 5.1.3.2. Strong government support for LTC
  • 5.1.4. Challenges
    • 5.1.4.1. Concern regarding limited approved products
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Long-acting Contraception Market, by Type

• 6.1. Introduction
• 6.2. Long-Acting Contraceptives
• 6.3. Short-Acting Contraceptives

7. Long-acting Contraception Market, by Product

• 7.1. Introduction
• 7.2. Injectables
• 7.3. Intrauterine Devices
• 7.4. Subdermal Implants

8. Long-acting Contraception Market, by Application

• 8.1. Introduction
• 8.2. Contraception
• 8.3. HIV
• 8.4. Schizophrenia

9. Long-acting Contraception Market, by End-use

• 9.1. Introduction
• 9.2. Drug Store
• 9.3. E-Commerce
• 9.4. Hospital

10. Americas Long-acting Contraception Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Long-acting Contraception Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Long-acting Contraception Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Bayer AG
• 3. DKT International
• 4. HRA Pharma SAS by Perrigo Company plc
• 5. Merck & Co., Inc.
• 6. Meril Life Sciences Pvt. Ltd.
• 7. Mona Lisa N.V.
• 8. OCON Healthcare
• 9. Pfizer Inc.
• 10. Pregna International Limited
• 11. Prosan International B.V.
• 12. SMB Corporation of India
• 13. Teva Pharmaceuticals Industries Ltd.
• 14. The Cooper Companies, Inc.
• 15. Viatris Inc.